DK3200582T3 - Sammensætninger, kits og fremgangsmåder til induktion af erhvervet cytoresistens under anvendelse af stressproteininducere - Google Patents

Sammensætninger, kits og fremgangsmåder til induktion af erhvervet cytoresistens under anvendelse af stressproteininducere Download PDF

Info

Publication number: DK3200582T3
Authority: DK; Denmark
Prior art keywords: kits; induction; compositions; methods; stress protein
Prior art date: 2014-09-29

Application number

DK15846121.0T

Other languages

English (en)

Inventor

Richard Zager

Ali Cm Johnson

Original Assignee

Fred Hutchinson Cancer Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-29

Filing date

2015-09-28

Publication date

2024-02-19

2015-09-28 Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center

2024-02-19 Application granted granted Critical

2024-02-19 Publication of DK3200582T3 publication Critical patent/DK3200582T3/da

Links

102000002812 Heat-Shock Proteins Human genes 0.000 title 1
108010004889 Heat-Shock Proteins Proteins 0.000 title 1
239000000411 inducer Substances 0.000 title 1
230000006698 induction Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Dentistry (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Biophysics (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

DK15846121.0T 2014-09-29 2015-09-28 Sammensætninger, kits og fremgangsmåder til induktion af erhvervet cytoresistens under anvendelse af stressproteininducere DK3200582T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462057047P	2014-09-29	2014-09-29
US201562212232P	2015-08-31	2015-08-31
PCT/US2015/052676 WO2016053882A2 (en)	2014-09-29	2015-09-28	Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers

Publications (1)

Publication Number	Publication Date
DK3200582T3 true DK3200582T3 (da)	2024-02-19

Family

ID=55631749

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15846121.0T DK3200582T3 (da)	2014-09-29	2015-09-28	Sammensætninger, kits og fremgangsmåder til induktion af erhvervet cytoresistens under anvendelse af stressproteininducere

Country Status (25)

Country	Link
US (6)	US10639321B2 (da)
EP (2)	EP4327808A3 (da)
JP (4)	JP6894837B2 (da)
KR (3)	KR102761197B1 (da)
CN (2)	CN107072190B (da)
AU (2)	AU2015324103C1 (da)
BR (1)	BR112017006531B1 (da)
CA (2)	CA3220985A1 (da)
DK (1)	DK3200582T3 (da)
ES (1)	ES2974905T3 (da)
FI (1)	FI3200582T3 (da)
HR (1)	HRP20240229T1 (da)
HU (1)	HUE065216T2 (da)
IL (3)	IL287607B (da)
LT (1)	LT3200582T (da)
MX (1)	MX2017004148A (da)
NZ (1)	NZ729754A (da)
PL (1)	PL3200582T3 (da)
PT (1)	PT3200582T (da)
RS (1)	RS65182B1 (da)
SG (2)	SG11201702080UA (da)
SI (1)	SI3200582T1 (da)
SM (1)	SMT202400067T1 (da)
WO (1)	WO2016053882A2 (da)
ZA (1)	ZA202305280B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3200582T1 (sl)	2014-09-29	2024-04-30	Fred Hutchinson Cancer Center	Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov
US20190358242A1 (en) *	2017-02-08	2019-11-28	Fred Hutchinson Cancer Research Center	Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
CN111936059B (zh) *	2018-03-27	2024-09-06	精密科学公司	稳定血红蛋白的方法和实施该方法的试剂
KR20210019459A (ko) *	2018-05-24	2021-02-22	레니버스 테라퓨틱스, 인크.	신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법
CN119488480A (zh) *	2019-02-28	2025-02-21	雷尼布斯治疗公司	新型铁组合物及其制造和使用方法
US11883371B2 (en) *	2020-03-23	2024-01-30	Renibus Therapeutics, Inc.	Stress test and treatment of chronic kidney disease
JPWO2022019235A1 (da) *	2020-07-22	2022-01-27
WO2022056378A1 (en) *	2020-09-11	2022-03-17	Renibus Therapeutics, Inc.	Method for treating cancer with kidney protection
WO2022191193A1 (ja) *	2021-03-12	2022-09-15	国立大学法人新潟大学	溶血反応により誘発される腎障害の抑制
US20230404958A1 (en) *	2021-03-12	2023-12-21	Niigata University	Agent for inhibiting renal damage induced by rhabdomyolysis
CN117957005A (zh) *	2021-07-12	2024-04-30	雷尼布斯治疗公司	用于治疗bk病毒的金属原卟啉
CN114487408B (zh) *	2022-02-09	2025-03-14	中南大学湘雅三医院	Arginase-2作为靶点在筛选诊断、预防和/或治疗药源性肾损伤的制品中的应用
CN114891707B (zh) *	2022-05-20	2024-04-05	中国科学院微生物研究所	重组菌株及其全细胞催化生产胆红素的方法
KR20250130402A (ko) *	2023-01-08	2025-09-01	레니버스 테라퓨틱스, 인크.	광민감성을 포함한 수술-후 합병증에 걸리기 쉬운 환자에서의 수술 전 기관의 보호 방법
WO2024182731A1 (en) *	2023-03-01	2024-09-06	Nevakar Injectables Inc.	Injectable compositions of vitamers of vitamin b12 and uses thereof
WO2025165353A1 (en) *	2024-01-31	2025-08-07	Renibus Therapeutics, Inc.	Novel stannic protoporfin compositions, methods of making, and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3579533A (en)	1968-03-18	1971-05-18	Antioch College	Preparation of porphin,substituted porphin and metal chelates thereof
GB1596298A (en)	1977-04-07	1981-08-26	Morgan Ltd P K	Method of and apparatus for detecting or measuring changes in the cross-sectional area of a non-magnetic object
US4657902A (en)	1985-03-25	1987-04-14	The Rockefeller University	Therapeutic use of tin mesoporphyrin
US4692440A (en)	1985-03-25	1987-09-08	The Rockefeller University	Therapeutic use of tin mesoporphyrin
US4668670A (en)	1986-06-20	1987-05-26	The Rockefeller University	Tin diiododeuteroporphyrin and therapeutic use thereof
US4782049A (en)	1986-12-08	1988-11-01	The Rockefeller University	Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis
DK0575545T3 (da)	1991-03-15	2003-09-15	Amgen Inc	Pegylering af polypeptider
US5108767A (en) *	1991-06-10	1992-04-28	Abbott Laboratories	Liquid nutritional product for persons receiving renal dialysis
US5274090A (en)	1992-11-09	1993-12-28	The Board Of Trustees Of The Leland Stanford Junior University	Tetraphenylporphyrin compounds and method
WO1994028906A1 (en)	1993-06-14	1994-12-22	The Rockefeller University	Treatment of neonatal hyperbilirubin with metalloporphyrin
DE19502255C2 (de) *	1995-01-25	1996-11-28	Windmoeller & Hoelscher	Vorrichtung zum Aufbringen von Zetteln aus Kunststoffolie auf flachliegende Werkstücke
US5804551A (en) *	1996-11-12	1998-09-08	Baxter International Inc.	Pretraumatic use of hemoglobin
US20100293669A2 (en)	1999-05-06	2010-11-18	Jingdong Liu	Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP2003512338A (ja)	1999-10-15	2003-04-02	メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ	造影剤および抗腫瘍薬として有用なコバラミン結合体
US6573258B2 (en)	2000-09-27	2003-06-03	Frontier Scientific, Inc.	Photodynamic porphyrin antimicrobial agents
US6517492B2 (en)	2001-02-22	2003-02-11	Texon Technologies Ltd.	Method and apparatus for assessment of cardiac function by monitoring movement of the trachea
AR037699A1 (es)	2001-12-04	2004-12-01	Monsanto Technology Llc	Maiz transgenico con fenotipo mejorado
JP4413523B2 (ja)	2002-04-26	2010-02-10	武田薬品工業株式会社	細胞死抑制剤
AU2003237349B2 (en)	2002-06-04	2010-06-03	Infacare Pharmaceutical Corporation	Preparation of metal mesoporphyrin halide compounds
US7375216B2 (en)	2002-06-04	2008-05-20	Infacare Pharmaceutical Corporation	Preparation of metal mesoporphyrin compounds
DK1546336T3 (da)	2002-09-18	2012-04-10	Mendel Biotechnology Inc	Polynukleotider og polypeptider i planter.
WO2004034887A2 (en) *	2002-10-18	2004-04-29	The General Hospital Corporation	Compositions, solutions, and methods used for transplantation
JP2004307404A (ja) *	2003-04-08	2004-11-04	Nipro Corp	人工酸素運搬体を含む医薬組成物
US7008937B2 (en)	2003-06-10	2006-03-07	Frontier Scientific, Inc.	Porphyrins and metalloporphyrins for inhibiting heme iron uptake
US7067659B2 (en)	2004-04-23	2006-06-27	Duke University	Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
CA2565701A1 (en)	2004-05-06	2005-11-17	Jonathan M. Barasch	Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
EP1773819A4 (en)	2004-07-15	2009-05-06	Univ Sydney	PORPHYRENE-BONDED METRONIDAZOLE AGAINST DENTISTRY PORPHYROMONAS GINGIVALIS
US7585527B2 (en)	2005-09-19	2009-09-08	Bala Venkataraman	Composition and method for treating iron deficiency anemia
US7960371B2 (en)	2006-10-04	2011-06-14	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
CA2691691C (en)	2007-06-20	2013-09-24	Seth J. Baum	Compositions and methods of treating chronic kidney disease
WO2009029836A2 (en) *	2007-08-31	2009-03-05	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes
PL2691398T3 (pl)	2011-03-30	2017-07-31	Infacare Pharmaceutical Corporation	Sposoby syntezy mezoporfiryn metali
CN103355655A (zh) *	2012-03-30	2013-10-23	北京因科瑞斯医药科技有限公司	一种具有改善营养性贫血功能的组合物及其制备方法
US9350026B2 (en)	2012-09-28	2016-05-24	Uchicago Argonne, Llc	Nanofibrous electrocatalysts
US20140273273A1 (en) *	2012-11-01	2014-09-18	Christie Mitchell Ballantyne	Biomarkers to improve prediction of heart failure risk
MX386702B (es)	2014-02-10	2025-03-19	Fred Hutchinson Cancer Center	Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
EP3140312B1 (en)	2014-05-05	2018-07-25	Centre National de la Recherche Scientifique (CNRS)	Porphyrin molecular catalysts for selective electrochemical reduction of co2 into co
SI3200582T1 (sl)	2014-09-29	2024-04-30	Fred Hutchinson Cancer Center	Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov

2015
- 2015-09-28 SI SI201531991T patent/SI3200582T1/sl unknown
- 2015-09-28 PL PL15846121.0T patent/PL3200582T3/pl unknown
- 2015-09-28 NZ NZ729754A patent/NZ729754A/en unknown
- 2015-09-28 HU HUE15846121A patent/HUE065216T2/hu unknown
- 2015-09-28 US US15/030,008 patent/US10639321B2/en active Active
- 2015-09-28 ES ES15846121T patent/ES2974905T3/es active Active
- 2015-09-28 JP JP2017516840A patent/JP6894837B2/ja active Active
- 2015-09-28 SG SG11201702080UA patent/SG11201702080UA/en unknown
- 2015-09-28 EP EP23208291.7A patent/EP4327808A3/en active Pending
- 2015-09-28 KR KR1020237030842A patent/KR102761197B1/ko active Active
- 2015-09-28 DK DK15846121.0T patent/DK3200582T3/da active
- 2015-09-28 PT PT158461210T patent/PT3200582T/pt unknown
- 2015-09-28 SM SM20240067T patent/SMT202400067T1/it unknown
- 2015-09-28 CA CA3220985A patent/CA3220985A1/en active Pending
- 2015-09-28 LT LTEPPCT/US2015/052676T patent/LT3200582T/lt unknown
- 2015-09-28 KR KR1020177011299A patent/KR102578217B1/ko active Active
- 2015-09-28 CA CA2963089A patent/CA2963089C/en active Active
- 2015-09-28 KR KR1020257002551A patent/KR20250020708A/ko active Pending
- 2015-09-28 CN CN201580052330.8A patent/CN107072190B/zh active Active
- 2015-09-28 MX MX2017004148A patent/MX2017004148A/es unknown
- 2015-09-28 IL IL287607A patent/IL287607B/en unknown
- 2015-09-28 CN CN202010969631.XA patent/CN112057470B/zh active Active
- 2015-09-28 HR HRP20240229TT patent/HRP20240229T1/hr unknown
- 2015-09-28 BR BR112017006531-2A patent/BR112017006531B1/pt active IP Right Grant
- 2015-09-28 EP EP15846121.0A patent/EP3200582B1/en active Active
- 2015-09-28 FI FIEP15846121.0T patent/FI3200582T3/fi active
- 2015-09-28 RS RS20240188A patent/RS65182B1/sr unknown
- 2015-09-28 AU AU2015324103A patent/AU2015324103C1/en active Active
- 2015-09-28 SG SG10201902831UA patent/SG10201902831UA/en unknown
- 2015-09-28 WO PCT/US2015/052676 patent/WO2016053882A2/en not_active Ceased
2017
- 2017-01-06 US US15/400,690 patent/US9844563B2/en active Active
- 2017-03-29 IL IL251455A patent/IL251455B/en active IP Right Grant
2018
- 2018-08-29 US US16/116,411 patent/US10912793B2/en active Active
2020
- 2020-04-20 AU AU2020202652A patent/AU2020202652B2/en active Active
- 2020-05-25 IL IL274891A patent/IL274891B/en unknown
2021
- 2021-01-04 US US17/140,295 patent/US11878029B2/en active Active
- 2021-06-03 JP JP2021093465A patent/JP2021130710A/ja active Pending
2022
- 2022-12-20 JP JP2022202892A patent/JP7549640B2/ja active Active
2023
- 2023-05-15 ZA ZA2023/05280A patent/ZA202305280B/en unknown
- 2023-09-12 US US18/465,768 patent/US12083145B2/en active Active
2024
- 2024-08-08 US US18/797,649 patent/US20250195556A1/en active Pending
- 2024-08-29 JP JP2024147222A patent/JP2024167327A/ja active Pending

Also Published As

Publication number	Publication date
JP7549640B2 (ja)	2024-09-11
KR102578217B1 (ko)	2023-09-15
IL274891B (en)	2021-12-01
MX2017004148A (es)	2017-07-07
AU2015324103B2 (en)	2020-05-21
US12083145B2 (en)	2024-09-10
ZA202305280B (en)	2023-12-20
CN107072190B (zh)	2020-10-09
KR20230132636A (ko)	2023-09-15
ES2974905T3 (es)	2024-07-02
US10912793B2 (en)	2021-02-09
US20210275567A1 (en)	2021-09-09
CN107072190A (zh)	2017-08-18
EP3200582B1 (en)	2023-11-15
KR20170057433A (ko)	2017-05-24
US20170112869A1 (en)	2017-04-27
AU2020202652A1 (en)	2020-05-14
IL251455A0 (en)	2017-05-29
CA2963089A1 (en)	2016-04-07
US20190091255A1 (en)	2019-03-28
WO2016053882A2 (en)	2016-04-07
SI3200582T1 (sl)	2024-04-30
CN112057470B (zh)	2022-11-15
AU2015324103A1 (en)	2017-03-23
IL287607B (en)	2022-07-01
FI3200582T3 (fi)	2024-02-14
HRP20240229T1 (hr)	2024-04-26
NZ729754A (en)	2023-01-27
US9844563B2 (en)	2017-12-19
LT3200582T (lt)	2024-03-12
SG10201902831UA (en)	2019-04-29
IL287607A (en)	2021-12-01
BR112017006531B1 (pt)	2023-01-24
KR20250020708A (ko)	2025-02-11
CA2963089C (en)	2024-01-09
SG11201702080UA (en)	2017-04-27
AU2015324103C1 (en)	2020-08-20
US20250195556A1 (en)	2025-06-19
CA3220985A1 (en)	2016-04-07
PT3200582T (pt)	2024-02-19
US20160271164A1 (en)	2016-09-22
JP6894837B2 (ja)	2021-06-30
US10639321B2 (en)	2020-05-05
WO2016053882A3 (en)	2016-05-06
CN112057470A (zh)	2020-12-11
US20240108646A1 (en)	2024-04-04
JP2024167327A (ja)	2024-12-03
JP2021130710A (ja)	2021-09-09
RS65182B1 (sr)	2024-03-29
EP4327808A3 (en)	2024-05-15
BR112017006531A2 (pt)	2017-12-19
SMT202400067T1 (it)	2024-03-13
EP3200582A4 (en)	2018-04-04
IL274891A (en)	2020-07-30
KR102761197B1 (ko)	2025-02-03
US11878029B2 (en)	2024-01-23
JP2017535522A (ja)	2017-11-30
IL251455B (en)	2020-06-30
EP4327808A2 (en)	2024-02-28
AU2020202652B2 (en)	2022-06-30
HUE065216T2 (hu)	2024-05-28
EP3200582A2 (en)	2017-08-09
JP2023054797A (ja)	2023-04-14
PL3200582T3 (pl)	2024-04-08

Publication	Publication Date	Title
DK3200582T3 (da)	2024-02-19	Sammensætninger, kits og fremgangsmåder til induktion af erhvervet cytoresistens under anvendelse af stressproteininducere
IL282372A (en)	2021-06-30	Haploid induction compositions and methods for use therefor
DK3303386T3 (da)	2024-10-28	Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3353210T3 (da)	2025-01-06	Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3386534T3 (da)	2020-11-30	Sammensætninger og fremgangsmåder til internalisering af enzymer
DK3295951T3 (da)	2020-07-20	Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
DK3250610T3 (da)	2023-10-30	Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3215532T3 (da)	2020-01-02	Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3185868T3 (da)	2022-05-23	Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3316909T3 (da)	2023-11-13	Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3230319T3 (da)	2022-10-17	Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3557998T3 (da)	2023-11-20	Sammensætninger, kompositioner og anvendelsesmetoder
DK3310812T3 (da)	2025-09-29	Anti-HER2-antistoffer og fremgangsmåder til anvendelse
DK3394065T3 (da)	2021-05-31	Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3514151T3 (da)	2025-07-21	Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3240895T3 (da)	2022-04-11	Sammensætninger og fremgangsmåder til proteinglykosylering
DK3129779T3 (da)	2020-09-07	Fremgangsmåder og sammensætninger til påvisning af fejlfoldede proteiner
DK3393655T3 (da)	2021-03-15	Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3209696T3 (da)	2021-08-09	Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3368578T3 (da)	2021-05-25	Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf
DK3104852T3 (da)	2024-11-11	Sammensætninger og fremgangsmåde til behandling af aldring og aldersbetingede sygdomme og symptomer
DK3107902T3 (da)	2021-05-03	Forbindelser og fremgangsmåder til at hæmme fascin
DK3110446T3 (da)	2022-02-28	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme